Transplant at Relapse: Is It Valuable?
Publicado: Vie Nov 14, 2014 7:09 am
Transplant at Relapse: Is It Valuable?
IMF
By Brian G.M. Durie, MD on November 13,
http://myeloma.org/MtEntryPage.action?s ... ble-1.html
Briam G:M:Durie, en su articulo, cita un ensayo del Prof Gordon Cook;busque el articulo.
Cita:"Prof. Gordon Cook's (University of Leeds, UK) presentation of the results of his Myeloma X Trial. Salvage transplant with melphalan 200mg/m2 (ASCT) was compared with simply Cytoxan by mouth (400 mg/m2 once/week for 3 months). Starting in 2008, 174 patients were randomized. The full results were published recently in Lancet Oncology. It was very helpful to see the benefit of salvage ASCT in this randomized setting. The data also confirmed the importance of length of prior remission and depth of response."
Busque el articulo en The Lancet y lo publico a continuacion.
"Altas dosis de quimioterapia más el trasplante autólogo de células madre como terapia de consolidación en pacientes con mieloma múltiple en recaída después de anterior trasplante de células madre autólogas (CNRI mieloma X recaída [juicio Intensivo]): un, abierto, aleatorizado, ensayo de fase 3"
http://translate.google.es/translate?hl ... rev=search
IMF
By Brian G.M. Durie, MD on November 13,
http://myeloma.org/MtEntryPage.action?s ... ble-1.html
Briam G:M:Durie, en su articulo, cita un ensayo del Prof Gordon Cook;busque el articulo.
Cita:"Prof. Gordon Cook's (University of Leeds, UK) presentation of the results of his Myeloma X Trial. Salvage transplant with melphalan 200mg/m2 (ASCT) was compared with simply Cytoxan by mouth (400 mg/m2 once/week for 3 months). Starting in 2008, 174 patients were randomized. The full results were published recently in Lancet Oncology. It was very helpful to see the benefit of salvage ASCT in this randomized setting. The data also confirmed the importance of length of prior remission and depth of response."
Busque el articulo en The Lancet y lo publico a continuacion.
"Altas dosis de quimioterapia más el trasplante autólogo de células madre como terapia de consolidación en pacientes con mieloma múltiple en recaída después de anterior trasplante de células madre autólogas (CNRI mieloma X recaída [juicio Intensivo]): un, abierto, aleatorizado, ensayo de fase 3"
http://translate.google.es/translate?hl ... rev=search